|Bid||7.08 x 1100|
|Ask||7.11 x 1800|
|Day's Range||6.88 - 7.13|
|52 Week Range||6.41 - 26.79|
|Beta (3Y Monthly)||1.32|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 4, 2017 - May 8, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||17.75|
The Santa Barbara, California-based company said it had a loss of 91 cents per share. The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
First Quarter 2019 Net Sales of $17.6 million, Growth of 20% year over year Provides 2019 Net Sales Outlook of $79 million to $83 million SANTA BARBARA, Calif., May 08, 2019.
Sientra (SIEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sientra, Inc. (SIEN), a medical aesthetics company (“Sientra” or the “Company”), announced today that the Company will release its first quarter 2019 financial results on Wednesday, May 8, 2019 after market close. Sientra will hold a conference call on Wednesday, May 8, 2019 at 4:30 p.m. ET to discuss the results. A press release disclosing the Company's financial results will be distributed at approximately 4:00 p.m. ET that same day.
It's easy to match the overall market return by buying an index fund. While individual stocks can be big winners, plenty more fail to generate satisfactory returns. That downside risk was realized by Sientra, Inc. (NASDAQ:SIE...
Sientra, Inc. (SIEN), a medical aesthetics company (“Sientra" or the “Company”), today announced it has provided an initial response to the U.S. Food and Drug Administration (“FDA”) related to a post-approval study Warning Letter issued on March 19, 2019 and will provide a comprehensive plan for compliance to FDA within 15 days.
The U.S. Food and Drug Administration has issued warning letters to Sientra Inc and a Johnson & Johnson unit for failing to comply with the post-approval study requirements for their breast implants. Last month, the FDA issued a statement https://www.fda.gov/MedicalDevices/Safety/LetterstoHealthCareProviders/ucm630863.htm warning doctors about a type of lymphoma linked to breast implants after receiving reports of the disease. The agency's letters http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20190319:nPn7rwbQSa, dated March 18, highlighted issues in the companies' post-approval studies, which included evaluating the long-term performance and safety of the implants, used for breast augmentation and reconstruction procedures.
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also plenty of examples of share prices declining precipitously after insidersRead More...
Stocks that moved substantially or traded heavily on Wednesday: Rite Aid Corp., up 4 cents to 72 cents The drugstore chain purged its top management, including CEO John Stanley, and said it will cut 400 ...
, a plastic surgery product maker, were falling hard Wednesday after the company reported a wider-than-expected fourth-quarter loss. Sientra lost 87 cents a share in the quarter, wider than analysts' calls for a loss of 67 cents. The company has missed earnings estimates in the last four quarters.
Sientra (SIEN) delivered earnings and revenue surprises of -28.36% and 0.83%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
The Santa Barbara, California-based company said it had a loss of 86 cents per share. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
Fourth Quarter 2018 Net Sales of $19.0 Million, Growth of 72% YoY on a GAAP Basis 2018 Net Sales of $68.1 Million, Growth of 86% YoY on a GAAP Basis and 46% YoY Pro Forma.
NEW YORK, NY / ACCESSWIRE / March 12, 2019 / Sientra, Inc. (NASDAQ: SIEN ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on March 12, 2019, 2018 at 4:30 PM ...
Sientra, Inc. (SIEN), a medical aesthetics company (“Sientra or the “Company”), announced today that the Company will release its fourth quarter and full year 2018 financial results on Tuesday, March 12, 2019 after market close. Sientra will hold a conference call on Tuesday, March 12, 2019 at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. A press release disclosing the Company's financial results will be distributed at approximately 1:00 p.m. PT/4:00 p.m. ET that same day.
NEW YORK, Feb. 26, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
SANTA BARBARA, Calif., Feb. 19, 2019 -- Sientra, Inc. (NASDAQ:SIEN), a medical aesthetics company, announced today that members of management are scheduled to present at the.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Investors are always looking for growth inRead More...